Journal of Clinical Oncology, Vol 16, 1174-1178, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group

J Latreille, J Pater, D Johnston, F Laberge, D Stewart, J Rusthoven, P Hoskins, B Findlay, E McMurtrie, L Yelle, C Williams, D Walde, S Ernst, H Dhaliwal, D Warr, F Shepherd, D Mee, L Nishimura, D Osoba and B Zee
Hotel-Dieu de Montreal Hospital, Quebec, Canada. jlatrei@cam.org

PURPOSE: To evaluate the roles of granisetron and dexamethasone for emesis control on days 2 through 7 after the administration of cisplatin in doses of 50 mg/m2 or greater to patients who had not previously received chemotherapy. PATIENTS AND METHODS: Four hundred thirty-five eligible and assessable patients were randomized to one of two arms in a double-blind fashion: arm A; granisetron 3 mg intravenous (i.v.) plus dexamethasone 10 mg i.v. prechemotherapy followed by granisetron 1 mg orally at 6 and 12 hours, then granisetron 1 mg orally and dexamethasone 8 mg orally twice daily on days 2 through 7 (219 patients); arm B; as in arm A but with placebo substituted for granisetron on days 2 through 7 (216 patients). All patients completed diaries in which episodes of emesis and severity of nausea were recorded. RESULTS: The addition of granisetron on days 2 through 7 had no discernable impact on nausea and vomiting during this period. CONCLUSION: The administration of a 5-hydroxytryptamine3, receptor (5- HT3) antagonist, in this case granisetron, after 24 hours conferred no benefit. This negative result needs to be assessed in light of conflicting literature, but at present it does not appear that the routine use of these drugs in this setting is justified.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. M Higa, M. L Auber, R. Altaha, D. Piktel, S. Kurian, G. Hobbs, and K. Landreth 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy Journal of Oncology Pharmacy Practice, December 1, 2006; 12(4): 201 - 209. [Abstract] [PDF]

				M. G. Kris, P. J. Hesketh, M. R. Somerfield, P. Feyer, R. Clark-Snow, J. M. Koeller, G. R. Morrow, L. W. Chinnery, M. J. Chesney, R. J. Gralla, et al. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006 J. Clin. Oncol., June 20, 2006; 24(18): 2932 - 2947. [Abstract] [Full Text] [PDF]

				H. J. Schmoll, M. S. Aapro, S. Poli-Bigelli, H.-K. Kim, K. Park, K. Jordan, J. von Pawel, H. Giezek, T. Ahmed, and C. Y. Chan Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment Ann. Onc., June 1, 2006; 17(6): 1000 - 1006. [Abstract] [Full Text] [PDF]

				The Antiemetic Subcommittee of the Multinational A Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference Ann. Onc., January 1, 2006; 17(1): 20 - 28. [Abstract] [Full Text] [PDF]

				O. Geling and H.-G. Eichler Should 5-Hydroxytryptamine-3 Receptor Antagonists Be Administered Beyond 24 Hours After Chemotherapy to Prevent Delayed Emesis? Systematic Re-Evaluation of Clinical Evidence and Drug Cost Implications J. Clin. Oncol., February 20, 2005; 23(6): 1289 - 1294. [Abstract] [Full Text] [PDF]

				P. J. Hesketh, S. M. Grunberg, R. J. Gralla, D. G. Warr, F. Roila, R. de Wit, S. P. Chawla, A. D. Carides, J. Ianus, M. E. Elmer, et al. The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin--The Aprepitant Protocol 052 Study Group J. Clin. Oncol., November 15, 2003; 21(22): 4112 - 4119. [Abstract] [Full Text] [PDF]

				W. C. Mertens, D. J. Higby, D. Brown, R. Parisi, J. Fitzgerald, E. M. Benjamin, and P. K. Lindenauer Improving the Care of Patients With Regard to Chemotherapy-Induced Nausea and Emesis: The Effect of Feedback to Clinicians on Adherence to Antiemetic Prescribing Guidelines J. Clin. Oncol., April 1, 2003; 21(7): 1373 - 1378. [Abstract] [Full Text] [PDF]

				R. J. Gralla, D. Osoba, M. G. Kris, P. Kirkbride, P. J. Hesketh, L. W. Chinnery, R. Clark-Snow, D. P. Gill, S. Groshen, S. Grunberg, et al. Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines J. Clin. Oncol., September 1, 1999; 17(9): 2971 - 2971. [Full Text] [PDF]